FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086094799> ?p ?o ?g. }

• W3086094799 endingPage "2737" @default.
• W3086094799 startingPage "2730" @default.
• W3086094799 abstract "The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid leukemia is survival, which is achieved by the vast majority of patients. The initial response to therapy provides a sensitive measure of future clinical outcome. Measurement of BCR-ABL1 transcript levels using real-time quantitative polymerase chain reaction standardized to the international reporting scale is now the principal recommended monitoring strategy. The method is used to assess early milestone responses and provides a guide for therapeutic intervention. When patients successfully traverse the critical first 12 months of TKI therapy, most will head towards another milestone response, deep molecular response (DMR, BCR-ABL1 ≤0.01%). DMR is essential for patients aiming to achieve treatment-free remission and a prerequisite for a trial of TKI discontinuation. The success of discontinuation trials has led to new treatment strategies in order for more patients to reach this milestone response. DMR has been incorporated into endpoints of clinical trials and is considered by some expert groups as the optimal treatment response. But is DMR a stable response and does it provide the ultimate protection against TKI resistance and death? Do we need to increase the sensitivity of detection of BCR-ABL1 to better identify the patients who would likely remain in treatment-free remission after TKI discontinuation? Is it necessary to switch current TKI therapy to a more potent inhibitor if the goal is to achieve DMR? These are issues that I will explore in this review." @default.
• W3086094799 created "2020-09-21" @default.
• W3086094799 creator A5011454613 @default.
• W3086094799 date "2020-09-17" @default.
• W3086094799 modified "2023-10-17" @default.
• W3086094799 title "Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?" @default.
• W3086094799 cites W1565948695 @default.
• W3086094799 cites W1827459324 @default.
• W3086094799 cites W1939978733 @default.
• W3086094799 cites W1968747503 @default.
• W3086094799 cites W1971880154 @default.
• W3086094799 cites W1973595070 @default.
• W3086094799 cites W1978526996 @default.
• W3086094799 cites W1981809014 @default.
• W3086094799 cites W1988106731 @default.
• W3086094799 cites W1988399039 @default.
• W3086094799 cites W2004081720 @default.
• W3086094799 cites W2009972868 @default.
• W3086094799 cites W2019633460 @default.
• W3086094799 cites W2021648831 @default.
• W3086094799 cites W2022050501 @default.
• W3086094799 cites W2028332702 @default.
• W3086094799 cites W2028959752 @default.
• W3086094799 cites W2032531836 @default.
• W3086094799 cites W2034469570 @default.
• W3086094799 cites W2036987278 @default.
• W3086094799 cites W2037544158 @default.
• W3086094799 cites W2041271955 @default.
• W3086094799 cites W2048228382 @default.
• W3086094799 cites W2050904392 @default.
• W3086094799 cites W2054462387 @default.
• W3086094799 cites W2057206328 @default.
• W3086094799 cites W2058216377 @default.
• W3086094799 cites W2064367288 @default.
• W3086094799 cites W2068645465 @default.
• W3086094799 cites W2072703295 @default.
• W3086094799 cites W2074301005 @default.
• W3086094799 cites W2077812841 @default.
• W3086094799 cites W2079517811 @default.
• W3086094799 cites W2084397515 @default.
• W3086094799 cites W2087374868 @default.
• W3086094799 cites W2091849791 @default.
• W3086094799 cites W2105783133 @default.
• W3086094799 cites W2106266094 @default.
• W3086094799 cites W2109339644 @default.
• W3086094799 cites W2112810605 @default.
• W3086094799 cites W2114878859 @default.
• W3086094799 cites W2117356576 @default.
• W3086094799 cites W2119424308 @default.
• W3086094799 cites W2124068666 @default.
• W3086094799 cites W2124097332 @default.
• W3086094799 cites W2133281983 @default.
• W3086094799 cites W2148743957 @default.
• W3086094799 cites W2162567359 @default.
• W3086094799 cites W2255775540 @default.
• W3086094799 cites W2260921597 @default.
• W3086094799 cites W2278657325 @default.
• W3086094799 cites W2339943063 @default.
• W3086094799 cites W2342845394 @default.
• W3086094799 cites W2342971750 @default.
• W3086094799 cites W2530814035 @default.
• W3086094799 cites W2557135819 @default.
• W3086094799 cites W2559066614 @default.
• W3086094799 cites W2560342075 @default.
• W3086094799 cites W2561977119 @default.
• W3086094799 cites W2588817469 @default.
• W3086094799 cites W2590307110 @default.
• W3086094799 cites W2615706081 @default.
• W3086094799 cites W2625840552 @default.
• W3086094799 cites W2626362851 @default.
• W3086094799 cites W2632073066 @default.
• W3086094799 cites W2744041560 @default.
• W3086094799 cites W2772405097 @default.
• W3086094799 cites W2792384496 @default.
• W3086094799 cites W2793798025 @default.
• W3086094799 cites W2800239311 @default.
• W3086094799 cites W2800303197 @default.
• W3086094799 cites W2802371729 @default.
• W3086094799 cites W2808074392 @default.
• W3086094799 cites W2891716460 @default.
• W3086094799 cites W2896643643 @default.
• W3086094799 cites W2896888521 @default.
• W3086094799 cites W2923808399 @default.
• W3086094799 cites W2925981115 @default.
• W3086094799 cites W2926466404 @default.
• W3086094799 cites W2928165967 @default.
• W3086094799 cites W2948433585 @default.
• W3086094799 cites W2952650636 @default.
• W3086094799 cites W2952885451 @default.
• W3086094799 cites W2960549986 @default.
• W3086094799 cites W2966615377 @default.
• W3086094799 cites W2969823991 @default.
• W3086094799 cites W2974755398 @default.
• W3086094799 cites W2975865348 @default.
• W3086094799 cites W2981754892 @default.
• W3086094799 cites W2981763967 @default.
• W3086094799 cites W2991317364 @default.
• W3086094799 cites W2991853710 @default.

• next